Compare EFOI & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EFOI | LPCN |
|---|---|---|
| Founded | 1985 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 19.1M |
| IPO Year | 2004 | 2011 |
| Metric | EFOI | LPCN |
|---|---|---|
| Price | $3.13 | $2.33 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.5K | ★ 105.8K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.75 | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,560,000.00 | $1,976,677.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $92.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.66 | $1.81 |
| 52 Week High | $9.84 | $12.37 |
| Indicator | EFOI | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 42.82 | 48.87 |
| Support Level | $1.85 | $2.16 |
| Resistance Level | $3.53 | $2.46 |
| Average True Range (ATR) | 0.26 | 0.15 |
| MACD | -0.09 | 0.06 |
| Stochastic Oscillator | 26.24 | 62.90 |
Energy Focus Inc specializes in designing, developing, manufacturing, and selling energy-efficient lighting systems and controls. It provides LED lighting solutions for both commercial and military maritime markets (MMM). Its core products include robust lighting fixtures and lamps for navy and military applications, Energy Storage Systems (ESS), Uninterruptible Power Supply (UPS), and tubular LED (TLED) lighting products, including battery backup units as well as general commercial and maritime lighting fixtures. The company operates in a single business segment that includes the marketing and sale of commercial and MMM lighting products and controls. The company generates a majority of its revenue from the sales of military maritime products in the United States.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.